Why Dr Reddy’s Stock Fell 10% After Missing Q1 Estimates by 1%

Published 27-07-2021, 04:45 pm
Updated 27-07-2021, 04:48 pm

By Aditya Raghunath

Investing.com -- Dr. Reddy’s Laboratories Ltd (NS:REDY) reported its numbers for Q1 FY22. Net profit came in at Rs 570.8 crore compared to Rs 594.6 crore in the corresponding quarter last fiscal. Revenue for Q1 FY22 came in at Rs 4,919 crore, up 11% compared to Rs 4,417.5 crores in Q1 FY21.

The stock closed at Rs 4,835.2, down 10.31% today. The reason for this drop is not the missed numbers. It is because Dr. Reddy’s has been issued a subpoena of documents for CIS (Commonwealth of Independent States) geographies, and that the company is investigating an anonymous complaint into improper payments in other countries.

In an exchange filing, Dr. Reddy’s said, ''The company has commenced a detailed investigation into an anonymous complaint. The complaint alleges that healthcare professionals in Ukraine and potentially in other countries were provided with improper payments by or on behalf of the Company in violation of US anti-corruption laws, specifically the US Foreign Corrupt Practices Act. A US law firm is conducting the investigation at the instruction of a committee of the Company's Board of Directors.''

The company has said that it has disclosed the ongoing investigation to the US DoJ (Department of Justice, SEC (Securities and Exchange Commission), and SEBI (Securities Exchange Board of India).

Dr. Reddy's said it is also in the process of responding to the subpoena. ''While the matter may result in government enforcement actions against the company in the United States and/or foreign jurisdictions, which could lead to civil and criminal sanctions under relevant laws, the probability of such action and the outcome are not reasonably ascertainable at this time,'' the company added.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.